Table 2.

Virological Suppression after 6 to 60 Months of First-Line Antiretroviral Therapy

Months on Antiretroviral Therapy	Cohorts, N	Participants, N				Descriptive Statistics			Random-Effects Meta-analysis
	Total	Total	Median	Interquartile Range		Median	Interquartile Range		Summary Estimate	95% Confidence Interval		τ2a
				Q1	Q3		Q1	Q3		Low	High
On-treatment analysis
6	100	116 051	173	84	453	87.2	78.7	91.3	84.9	83.5	86.3	0.03
12	117	103 632	174	78	427	87.7	80.8	91.9	85.6	84.4	86.9	0.04
24	45	39 694	203	78	475	86.0	80.5	91.9	84.4	82.0	86.9	0.05
36	21	18 729	373	163	980	90.1	82.5	93.6	88.5	85.5	91.4	0.06
48	13	4673	201	104	384	90.9	85.1	94.6	88.6	84.2	93.0	0.09
60	6	1433	117	60	505	86.6	78.6	94.1	85.2	76.6	93.9	0.09
Intention-to-treat analysis
6	40	47 838	106	40	371	72.9	63.8	82.3	74.7	72.2	77.2	0.02
12	67	40 938	153	66	351	71.9	59.6	77.6	67.3	63.6	71.0	0.10
24	23	6332	142	66	321	65.0	52.4	72.2	64.6	60.8	68.4	0.03
36	4	1411	309	160	546	63.0	61.3	75.1	68.1	58.0	78.2	0.03
48	4	504	130	66	187	59.0	51.4	72.4	61.8	44.0	79.7	0.13

^a τ² is a measure of between-study heterogeneity that is less affected by the number of studies than other common measures.